ResMed Aktie News

One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatments already.

Eli Lilly stock popped Wednesday — and pushed ResMed stock lower — after its weight-loss drug reduced sleep apnea symptoms.

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may als...

Once you reach the age of 73, there's no getting around Required Minimum Distributions (RMDs). Yet while there's no getting around making this compulsory withdrawal from your 401(k) or IRA, consider investing it rather than spending it.

ResMed announced the results of its 2024 Global Sleep Survey, uncovering a world in sleep crisis and encouraging people to discover their sleep superpowers

Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night.

ResMed makes medical devices for sleep apnea and COPD, a potential market of over a billion people. DexCom is a market leader in continuous glucose monitoring devices for diabetes patients.

Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX:...